Edwards Lifesciences (EW) Competitors

Henry Schein (NASDAQ:HSIC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Is HSIC or EW more profitable?

Edwards Lifesciences has a net margin of 72.96% compared to Henry Schein's net margin of 3.05%. Edwards Lifesciences' return on equity of 15.01% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	3.05%	14.36%	5.52%
Edwards Lifesciences	72.96%	15.01%	11.56%

Which has better earnings and valuation, HSIC or EW?

Edwards Lifesciences has lower revenue, but higher earnings than Henry Schein. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$12.67B	0.65	$390M	$3.10	21.86
Edwards Lifesciences	$5.44B	8.74	$4.17B	$6.95	11.65

Does the media refer more to HSIC or EW?

In the previous week, Edwards Lifesciences had 5 more articles in the media than Henry Schein. MarketBeat recorded 27 mentions for Edwards Lifesciences and 22 mentions for Henry Schein. Edwards Lifesciences' average media sentiment score of 1.47 beat Henry Schein's score of 0.81 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edwards Lifesciences	24 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals hold more shares of HSIC or EW?

96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 1.1% of Henry Schein shares are owned by insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more risk & volatility, HSIC or EW?

Henry Schein has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Do analysts prefer HSIC or EW?

Henry Schein presently has a consensus price target of $76.67, suggesting a potential upside of 13.11%. Edwards Lifesciences has a consensus price target of $85.90, suggesting a potential upside of 6.08%. Given Henry Schein's higher possible upside, equities analysts plainly believe Henry Schein is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.42
Edwards Lifesciences	1 Sell rating(s)	10 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.65

Summary

Edwards Lifesciences beats Henry Schein on 12 of the 17 factors compared between the two stocks.